ClinicalTrials.gg
CompletedNCT05962151RIVERUpdated Mar 30, 2026Results posted

Refractory Chronic Cough Improvement Via NAL ER (RIVER)

A Phase 2 interventional study of NAL ER and Placebo in Refractory Chronic Cough, sponsored by Trevi Therapeutics. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Trevi Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Chronic Cough with a site in United Kingdom — 4 open to participants now, 6 under way, 1 of them phase 3. Chronic Cough · United Kingdom.

Enrollment
18th of 29
66 · median 100
Started
2023
with 2 others
Phase 2
15 of 36
2 open now
Registered
29th of 36
by date
Lead sponsor
2 of 36
Trevi Therapeutics

Among the 36 studies in Chronic Cough with a site in United Kingdom, this one is the 18th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2023, is one of 15 in phase 2, and was the 29th registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

4 of the 36 studies in Chronic Cough with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Chronic Cough with a site in United Kingdom, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the effect of NAL ER on 24-hour cough frequency and to assess safety and tolerability of NAL-ER for treatment of refractory chronic cough.

03

Conditions studied

  • Refractory Chronic Cough

Keywords

  • RCC
  • Cough
  • Nalbuphine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of chronic cough (RCC) for at least one year
  • Chest radiograph or CT of thorax within 24 months or during screening not demonstrating any significant abnormalities contributing to RCC

Exclusion Criteria:

  • Diagnosis of sleep apnea
  • Respiratory tract infection within 6 weeks of Baseline
  • History of bronchiectasis, , or IPF
  • History of uncontrolled asthma
  • Current smokers/vapers, quit smoking with \<=12 months, using nicotine supplements, or history of >=20 pack years
  • History of major psychiatric disorder
  • History of substance abuse
  • Pregnant or lactating females
  • Known intolerance to opioids
  • Abnormal kidney or liver functions based on Screening lab results.
  • Known to nalbuphine or to NAL ER
  • Previous participation in a nalbuphine ER clinical study
  • Use of opiates, benzodiazepines, or MAOIs within 14 days of Baseline
  • Use of pregabalin, gabapentin, thalidomide for treatment of cough within 14 days of Baseline
  • Use of ACE inhibitors within 12 weeks of Baseline
  • Use of a medication having a "known risk" of Torsade de Pointes (categorized as "KR" on the Credible Meds® website.) 4 weeks prior to Baseline
  • Use of unstable doses of medications associated with a potential risk of but not clearly associated with Torsade de Pointes within 4 weeks of screening.
  • Use of unstable doses of cough suppressants within 14 days of Baseline
  • Use of unstable doses of medications that affect serotonergic neurotransmission that may cause serotonin syndrome with opioids within14 days of Baseline
  • Use of unstable doses of P450 isozyme inhibitors/inducers within 14 days of Baseline

Other protocol defined inclusion/exclusion criteria applied.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    First NAL ER, then Placebo

    Participants received NAL ER at escalating doses (27 mg QD to BID, 54 mg BID, and 108 mg BID) in Treatment Period 1, followed by placebo matched to NAL ER in Treatment Period 2.

    Drug: NAL ER · Drug: Placebo

  • Experimental
    First Placebo then NAL ER

    Participants received placebo matched to NAL ER in Treatment Period 1, followed by NAL ER at escalating doses (27 mg QD to BID, 54 mg BID, and 108 mg BID) in Treatment Period 2.

    Drug: NAL ER · Drug: Placebo

Interventions

  • DrugNAL ER

    Oral tablets

    Also known as: Nalbuphine

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Relative Change From Baseline in 24-hour Cough Frequency at Day 21

    Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.

    Time frame: Baseline, Day 21

Secondary outcomes

  1. Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE was defined as any AE that occurs after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

    Time frame: Up to Week 15

  2. Number of Participants With Clinically Significant Abnormalities in Laboratory Assessments

    The clinical laboratory parameters included urinalysis, hematology, serum chemistry and coagulation. Clinical significance was determined by the investigator.

    Time frame: Up to Week 15

  3. Number of Participants With Clinically Significant Changes in Vital Sign Parameters

    Vital signs measurements included blood pressure, heart rate, respiration rate, body temperature, pulse oximetry, and weight. Clinical significance was determined by the investigator.

    Time frame: Up to Week 15

  4. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)

    Changes in ECG data such as heart rate, rhythm, and other clinically significant abnormalities (left ventricular hypertrophy, pathological Q-waves) were measured. Clinical significance was determined by the investigator.

    Time frame: Up to Week 15

  5. Number of Participants With Clinically Significant Changes in Physical Examination Parameters

    Physical examination included examination of the following body systems: general appearance, eyes, ears, nose, throat, head and neck, chest and lungs, cardiovascular, abdomen, musculoskeletal, lymphatic, dermatological, neurological, and extremities. Clinical significance was determined by the investigator.

    Time frame: Up to Week 15

  6. Relative Change From Baseline in 24-hour Cough Frequency at Days 7 and 14

    Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.

    Time frame: Baseline, Days 7 and 14

  7. Percentage of Responders With >=30%, 50% and 75% Reduction in 24-hour Cough Frequency

    Responders were defined as those with ≥30%, ≥50%, or ≥75% reduction in 24-hour cough frequency from Baseline at Days 7, 14, or 21.

    Time frame: Days 7, 14, and 21

  8. Relative Change From Baseline in Awake Cough Frequency at Days 7, 14, and 21

    Awake cough was defined as cough that occurs between the time that the participant is awaken 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.

    Time frame: Baseline, Days 7, 14, and 21

  9. Relative Change From Baseline in Sleep Cough Frequency at Days 7, 14, and 21

    Sleep cough frequency was intended as the average coughs per hour while the participant was flagged as being asleep. Assessment was done using objective digital cough monitoring. Percent change in cough frequency (coughs per hour) from baseline was assessed. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.

    Time frame: Baseline, Days 7, 14 and 21

  10. Change From Baseline in Cough Severity Visual Analogue Scale (CS-VAS) at Days 7, 14, and 21

    The CS-VAS is a brief, easily administered patient reported outcome (PRO) questionnaire that is used to assess cough severity in both acute and chronic cough. CS-VAS is a 1-item scale that rates the severity of participants' cough from 0 millimeter (mm) where 0 indicated "no cough" and 100 represented "worst cough ever". A negative change from baseline indicates improvement.

    Time frame: Baseline, Days 7, 14, and 21

  11. Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Day 21

    LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status.

    Time frame: Baseline, Day 21

  12. Change From Baseline in Patient-Reported Cough Frequency (PR-CF) at Days 7, 14, and 21

    Patient-Reported Cough Frequency (PR-CF) is a daily, self-reported, 1 item scale, PRO that is used to assess cough frequency. Participants rate their cough frequency over the past 24 hours using a 5-point Likert scale (0- to 4: 0 = Not at all, 1 = Rarely, 2 = Occasionally, 3 = Frequently, 4 = Almost constantly). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.

    Time frame: Baseline, Days 7, 14, and 21

  13. Percentage of PR-CF Responders With at Least One Category Improvement at Days 7, 14, and 21

    PR-CF is a daily, self-reported, 1 item scale, PRO that is used to assess cough frequency. Participants rate their cough frequency over the past 24 hours using a 5-point Likert scale (0 to 4: 0 = Not at all, 1 = Rarely, 2 = Occasionally, 3 = Frequently, 4 = Almost constantly). A higher score indicates more severe symptoms. PR CF responders were defined as participants with at least a one category improvement at Days 7, 14, and 21.

    Time frame: Days 7, 14, and 21

  14. Change From Baseline in Patient Global Impression of Severity (PGI-S) Cough at Days 7, 14, and 21

    The PGI-S Cough scale is a self-reported, single-item categorical scale that is increasingly used when assessing chronic cough. Participants rate the severity of their cough in the last week with a 4-point Likert scale ranging from 0 to 3 (0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.

    Time frame: Baseline, Days 7, 14 and 21

  15. Patient Global Impression of Change for Cough (PGI-C) Score at Days 7, 14, and 21

    The PGI-C Cough scale is a self-reported, single-item categorical scale that is increasingly used when assessing chronic cough. Participants rate the severity of their cough in the last week with a 7-point Likert scale ranging from 0 to 7 (0 = No Cough, 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, or 7 = Much worse). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.

    Time frame: Days 7, 14, and 21

  16. Change From Baseline in Clinicians Global Impression of Cough Severity Score (CGI-S) at Day 21

    The CGI-S Cough scale is an investigator-reported, single-item categorical scale that is increasingly used when assessing the severity of the condition. Investigator rate the severity of their cough in the last week with a 4-point Likert scale ranging from 0 to 3 (0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.

    Time frame: Baseline, Day 21

  17. Clinicians Global Impression of Change for Cough Score (CGI-C) at Day 21

    The PGI-C Cough scale is an investigator-reported, single-item categorical scale that is increasingly used when assessing the investigator's belief of the participant's overall improvement pre-treatment baseline. Investigator rate the change in improvement in the last week with a 7-point Likert scale ranging from 1 to 7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6= Much worse, or 7= Very much worse). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.

    Time frame: Day 21

07

Results

Posted Mar 30, 2026

Participant flow

Participants were enrolled at 14 sites from 30 November 2023 to 06 January 2025.

Treatment Period 1 (21 Days)
Participant flow — Treatment Period 1 (21 Days)
MilestoneFirst NAL ER Then PlaceboFirst Placebo Then NAL ER
Started3432
Full analysis set (fas)3029
Completed2829
Not completed63
Withdrew: Adverse event51
Withdrew: Withdrawal by subject12
Washout Period (21 Days)
Participant flow — Washout Period (21 Days)
MilestoneFirst NAL ER Then PlaceboFirst Placebo Then NAL ER
Started2829
Completed2829
Not completed00
Treatment Period 2 (21 Days)
Participant flow — Treatment Period 2 (21 Days)
MilestoneFirst NAL ER Then PlaceboFirst Placebo Then NAL ER
Started2829
Completed2724
Not completed15
Withdrew: Adverse event04
Withdrew: Withdrawal by subject10
Withdrew: Reason not specified01

Outcome measures

PrimaryRelative Change From Baseline in 24-hour Cough Frequency at Day 21

Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.

Time frame:
Baseline, Day 21
Reported as:
Mean · coughs per hour
Relative Change From Baseline in 24-hour Cough Frequency at Day 21
coughs per hourNAL ERPlacebo
Relative Change From Baseline in 24-hour Cough Frequency at Day 21-64.92 ± 36.552-9.36 ± 40.952
Statistical analysis
  • NAL ER vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = <0.0001 (Repeated measures model with the response, sequence, time, and the treatment\*time interaction as fixed effects, and sex as covariates, site as a random effect, and participant as a random repeated effect.) · Least square (ls) mean difference: -1.30 · 95% CI -1.6 to -1.0
SecondaryNumber of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE was defined as any AE that occurs after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

Time frame:
Up to Week 15
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs)
ParticipantsNAL ERPlacebo
Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs)5032
SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Assessments

The clinical laboratory parameters included urinalysis, hematology, serum chemistry and coagulation. Clinical significance was determined by the investigator.

Time frame:
Up to Week 15
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Assessments
ParticipantsNAL ERPlacebo
Urinalysis00
Hematology00
Serum Chemistry11
Coagulation00
SecondaryNumber of Participants With Clinically Significant Changes in Vital Sign Parameters

Vital signs measurements included blood pressure, heart rate, respiration rate, body temperature, pulse oximetry, and weight. Clinical significance was determined by the investigator.

Time frame:
Up to Week 15
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Sign Parameters
ParticipantsNAL ERPlacebo
Blood Pressure114
Heart Rate22
Respiration Rate00
Body Temperature00
Pulse Oximetry00
Weight20
SecondaryNumber of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)

Changes in ECG data such as heart rate, rhythm, and other clinically significant abnormalities (left ventricular hypertrophy, pathological Q-waves) were measured. Clinical significance was determined by the investigator.

Time frame:
Up to Week 15
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
ParticipantsNAL ERPlacebo
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)10
SecondaryNumber of Participants With Clinically Significant Changes in Physical Examination Parameters

Physical examination included examination of the following body systems: general appearance, eyes, ears, nose, throat, head and neck, chest and lungs, cardiovascular, abdomen, musculoskeletal, lymphatic, dermatological, neurological, and extremities. Clinical significance was determined by the investigator.

Time frame:
Up to Week 15
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Physical Examination Parameters
ParticipantsNAL ERPlacebo
Number of Participants With Clinically Significant Changes in Physical Examination Parameters1012
SecondaryRelative Change From Baseline in 24-hour Cough Frequency at Days 7 and 14

Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.

Time frame:
Baseline, Days 7 and 14
Reported as:
Mean · coughs per hour
Relative Change From Baseline in 24-hour Cough Frequency at Days 7 and 14
coughs per hourNAL ERPlacebo
Change at Day 7-56.12 ± 30.7337.70 ± 39.929
Change at Day 14-59.20 ± 33.304-5.14 ± 40.457
Statistical analysis
  • NAL ER vs Placebo · MMRM · p = <0.0001 (Repeated measures model with the response, sequence, time, and the treatment\*time interaction as fixed effects, and sex as covariates, site as a random effect, and participant as a random repeated effect.) · Least square (ls) mean difference: -1.12 · 95% CI -1.4 to -0.8
  • NAL ER vs Placebo · MMRM · p = 0.0010 (Repeated measures model with the response, sequence, time, and the treatment\*time interaction as fixed effects, and sex as covariates, site as a random effect, and participant as a random repeated effect.) · Least square (ls) mean difference: -1.15 · 95% CI -1.4 to -0.9
SecondaryPercentage of Responders With >=30%, 50% and 75% Reduction in 24-hour Cough Frequency

Responders were defined as those with ≥30%, ≥50%, or ≥75% reduction in 24-hour cough frequency from Baseline at Days 7, 14, or 21.

Time frame:
Days 7, 14, and 21
Reported as:
Number · percentage of participants
Percentage of Responders With >=30%, 50% and 75% Reduction in 24-hour Cough Frequency
percentage of participantsNAL ERPlacebo
>=30% Reduction at Day 778.9 (66.1 to 88.6)14.5 (6.5 to 26.7)
>=30% Reduction at Day 1476.4 (63.0 to 86.8)24.1 (13.5 to 37.6)
>=30% Reduction at Day 2187.0 (75.1 to 94.6)30.2 (18.3 to 44.3)
>=50% Reduction at Day 763.2 (49.3 to 75.6)3.6 (0.4 to 12.5)
>=50% Reduction at Day 1467.3 (53.3 to 79.3)11.1 (4.2 to 22.6)
>=50% Reduction at Day 2179.6 (66.5 to 89.4)15.1 (6.7 to 27.6)
>=75% Reduction at Day 738.6 (26.0 to 52.4)0.0 (0.0 to 6.5)
>=75% Reduction at Day 1441.8 (28.7 to 55.9)1.9 (0.0 to 9.9)
>=75% Reduction at Day 2153.7 (39.6 to 67.4)1.9 (0.0 to 10.1)
Statistical analysis
  • NAL ER vs Placebo · Exact Logistic Regression Model · p = <0.0001 (Exact Logistic Regression Model: Treatment and treatment sequence as fixed effects, and sex as a covariate.) · Odds ratio (or): 20.48 · 95% CI 7.32 to 64.97
  • NAL ER vs Placebo · Exact Logistic Regression Model · p = <0.0001 (Exact Logistic Regression Model: Treatment and treatment sequence as fixed effects, and sex as a covariate.) · Odds ratio (or): 9.65 · 95% CI 3.82 to 26.23
  • NAL ER vs Placebo · Exact Logistic Regression Model · p = <0.0001 (Exact Logistic Regression Model: Treatment and treatment sequence as fixed effects, and sex as a covariate.) · Odds ratio (or): 14.88 · 95% CI 5.25 to 48.37
  • NAL ER vs Placebo · Exact Logistic Regression Model · p = <0.0001 (Exact Logistic Regression Model: Treatment and treatment sequence as fixed effects, and sex as a covariate.) · Odds ratio (or): 40.51 · 95% CI 9.25 to 372.90
  • NAL ER vs Placebo · Exact Logistic Regression Model · p = <0.0001 (Exact Logistic Regression Model: Treatment and treatment sequence as fixed effects, and sex as a covariate.) · Odds ratio (or): 14.99 · 95% CI 5.25 to 50.23
  • NAL ER vs Placebo · Exact Logistic Regression Model · p = <0.0001 (Exact Logistic Regression Model: Treatment and treatment sequence as fixed effects, and sex as a covariate.) · Odds ratio (or): 19.82 · 95% CI 7.01 to 63.26
  • NAL ER vs Placebo · Exact Logistic Regression Model · p = <0.0001 (Exact Logistic Regression Model: Treatment and treatment sequence as fixed effects, and sex as a covariate.) · Odds ratio (or): 52.55 · 95% CI 10.81 to 999.9
  • NAL ER vs Placebo · Exact Logistic Regression Model · p = <0.0001 (Exact Logistic Regression Model: Treatment and treatment sequence as fixed effects, and sex as a covariate.) · Odds ratio (or): 35.64 · 95% CI 5.31 to 999.9
  • NAL ER vs Placebo · Exact Logistic Regression Model · p = <0.0001 (Exact Logistic Regression Model: Treatment and treatment sequence as fixed effects, and sex as a covariate.) · Odds ratio (or): 55.29 · 95% CI 8.25 to 999.9
SecondaryRelative Change From Baseline in Awake Cough Frequency at Days 7, 14, and 21

Awake cough was defined as cough that occurs between the time that the participant is awaken 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.

Time frame:
Baseline, Days 7, 14, and 21
Reported as:
Mean · coughs per hour
Relative Change From Baseline in Awake Cough Frequency at Days 7, 14, and 21
coughs per hourNAL ERPlacebo
Change at Day 7-54.17 ± 31.9965.25 ± 37.779
Change at Day 14-59.29 ± 32.437-5.01 ± 37.037
Change at Day 21-64.96 ± 34.332-9.37 ± 39.322
SecondaryRelative Change From Baseline in Sleep Cough Frequency at Days 7, 14, and 21

Sleep cough frequency was intended as the average coughs per hour while the participant was flagged as being asleep. Assessment was done using objective digital cough monitoring. Percent change in cough frequency (coughs per hour) from baseline was assessed. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.

Time frame:
Baseline, Days 7, 14 and 21
Reported as:
Mean · coughs per hour
Relative Change From Baseline in Sleep Cough Frequency at Days 7, 14, and 21
coughs per hourNAL ERPlacebo
Change at Day 7-32.86 ± 198.03653.24 ± 252.834
Change at Day 14-7.11 ± 341.28018.55 ± 165.295
Change at Day 21-15.70 ± 244.51630.11 ± 207.430
SecondaryChange From Baseline in Cough Severity Visual Analogue Scale (CS-VAS) at Days 7, 14, and 21

The CS-VAS is a brief, easily administered patient reported outcome (PRO) questionnaire that is used to assess cough severity in both acute and chronic cough. CS-VAS is a 1-item scale that rates the severity of participants' cough from 0 millimeter (mm) where 0 indicated "no cough" and 100 represented "worst cough ever". A negative change from baseline indicates improvement.

Time frame:
Baseline, Days 7, 14, and 21
Reported as:
Mean · millimeter
Change From Baseline in Cough Severity Visual Analogue Scale (CS-VAS) at Days 7, 14, and 21
millimeterNAL ERPlacebo
Change at Day 7-22.2 ± 22.79-2.9 ± 13.82
Change at Day 14-29.7 ± 22.72-4.1 ± 15.34
Change at Day 21-29.9 ± 23.75-5.3 ± 15.96
Statistical analysis
  • NAL ER vs Placebo · MMRM · p = <0.0001 (Repeated measures model with the response, sequence, time, and the treatment\*time interaction as fixed effects, and sex as covariates, site as a random effect, and participant as a random repeated effect.) · Ls mean difference: -19.79 · 95% CI -27.0 to -12.6
  • NAL ER vs Placebo · MMRM · p = <0.0001 (Repeated measures model with the response, sequence, time, and the treatment\*time interaction as fixed effects, and sex as covariates, site as a random effect, and participant as a random repeated effect.) · Ls mean difference: -25.63 · 95% CI -32.8 to -18.5
  • NAL ER vs Placebo · MMRM · p = <0.0001 (Repeated measures model with the response, sequence, time, and the treatment\*time interaction as fixed effects, and sex as covariates, site as a random effect, and participant as a random repeated effect.) · Ls mean difference: -24.04 · 95% CI -31.2 to -16.9
SecondaryChange From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Day 21

LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status.

Time frame:
Baseline, Day 21
Reported as:
Mean · score on a scale
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Day 21
score on a scaleNAL ERPlacebo
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Day 214.50 ± 3.8180.25 ± 2.476
Statistical analysis
  • NAL ER vs Placebo · Paired t-Test · p = <0.0001 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: 4.06 · 95% CI 2.7 to 5.4
SecondaryChange From Baseline in Patient-Reported Cough Frequency (PR-CF) at Days 7, 14, and 21

Patient-Reported Cough Frequency (PR-CF) is a daily, self-reported, 1 item scale, PRO that is used to assess cough frequency. Participants rate their cough frequency over the past 24 hours using a 5-point Likert scale (0- to 4: 0 = Not at all, 1 = Rarely, 2 = Occasionally, 3 = Frequently, 4 = Almost constantly). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.

Time frame:
Baseline, Days 7, 14, and 21
Reported as:
Mean · score on a scale
Change From Baseline in Patient-Reported Cough Frequency (PR-CF) at Days 7, 14, and 21
score on a scaleNAL ERPlacebo
Change at Day 7-0.74 ± 0.8120.02 ± 0.685
Change at Day 14-0.92 ± 0.763-0.13 ± 0.703
Change at Day 21-1.08 ± 0.805-0.27 ± 0.811
Statistical analysis
  • NAL ER vs Placebo · Paired t-Test · p = <0.0001 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: -0.76 · 95% CI -1.1 to -0.4
  • NAL ER vs Placebo · Paired t-Test · p = <0.0001 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: -0.79 · 95% CI -1.1 to -0.5
  • NAL ER vs Placebo · Paired t-Test · p = <0.0001 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: -0.81 · 95% CI -1.2 to -0.5
SecondaryPercentage of PR-CF Responders With at Least One Category Improvement at Days 7, 14, and 21

PR-CF is a daily, self-reported, 1 item scale, PRO that is used to assess cough frequency. Participants rate their cough frequency over the past 24 hours using a 5-point Likert scale (0 to 4: 0 = Not at all, 1 = Rarely, 2 = Occasionally, 3 = Frequently, 4 = Almost constantly). A higher score indicates more severe symptoms. PR CF responders were defined as participants with at least a one category improvement at Days 7, 14, and 21.

Time frame:
Days 7, 14, and 21
Reported as:
Number · percentage of participants
Percentage of PR-CF Responders With at Least One Category Improvement at Days 7, 14, and 21
percentage of participantsNAL ERPlacebo
Day 762.3 (47.9 to 75.2)18.0 (8.6 to 31.4)
Day 1469.2 (54.9 to 81.3)27.1 (15.3 to 41.8)
Day 2175.5 (61.7 to 86.2)34.7 (21.7 to 49.6)
Statistical analysis
  • NAL ER vs Placebo · McNemar's Test · p = <0.0001 (McNemar's test was used to compare binary responder proportions between NAL ER and Placebo.)
  • NAL ER vs Placebo · McNemar's Test · p = <0.0001 (McNemar's test was used to compare binary responder proportions between NAL ER and Placebo.)
  • NAL ER vs Placebo · McNemar's Test · p = 0.0002 (McNemar's test was used to compare binary responder proportions between NAL ER and Placebo.)
SecondaryChange From Baseline in Patient Global Impression of Severity (PGI-S) Cough at Days 7, 14, and 21

The PGI-S Cough scale is a self-reported, single-item categorical scale that is increasingly used when assessing chronic cough. Participants rate the severity of their cough in the last week with a 4-point Likert scale ranging from 0 to 3 (0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.

Time frame:
Baseline, Days 7, 14 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Patient Global Impression of Severity (PGI-S) Cough at Days 7, 14, and 21
score on a scaleNAL ERPlacebo
Change at Day 7-0.45 ± 0.6010.06 ± 0.627
Change at Day 14-0.84 ± 0.757-0.09 ± 0.564
Change at Day 21-0.98 ± 0.751-0.09 ± 0.646
Statistical analysis
  • NAL ER vs Placebo · Paired t-Test · p = 0.0003 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: -0.48 · 95% CI -0.7 to -0.2
  • NAL ER vs Placebo · Paired t-Test · p = <0.0001 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: -0.71 · 95% CI -1.0 to -0.4
  • NAL ER vs Placebo · Paired t-Test · p = <0.0001 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: -0.83 · 95% CI -1.1 to -0.5
SecondaryPatient Global Impression of Change for Cough (PGI-C) Score at Days 7, 14, and 21

The PGI-C Cough scale is a self-reported, single-item categorical scale that is increasingly used when assessing chronic cough. Participants rate the severity of their cough in the last week with a 7-point Likert scale ranging from 0 to 7 (0 = No Cough, 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, or 7 = Much worse). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.

Time frame:
Days 7, 14, and 21
Reported as:
Mean · score on a scale
Patient Global Impression of Change for Cough (PGI-C) Score at Days 7, 14, and 21
score on a scaleNAL ERPlacebo
Day 72.64 ± 1.1034.04 ± 1.213
Day 142.41 ± 1.3323.91 ± 1.229
Day 212.07 ± 1.1893.71 ± 1.066
Statistical analysis
  • NAL ER vs Placebo · Paired t-Test · p = <0.0001 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: -1.35 · 95% CI -1.8 to -0.9
  • NAL ER vs Placebo · Paired t-Test · p = <0.0001 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: -1.49 · 95% CI -2.0 to -1.0
  • NAL ER vs Placebo · Paired t-Test · p = <0.0001 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: -1.56 · 95% CI -2.0 to -1.1
SecondaryChange From Baseline in Clinicians Global Impression of Cough Severity Score (CGI-S) at Day 21

The CGI-S Cough scale is an investigator-reported, single-item categorical scale that is increasingly used when assessing the severity of the condition. Investigator rate the severity of their cough in the last week with a 4-point Likert scale ranging from 0 to 3 (0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.

Time frame:
Baseline, Day 21
Reported as:
Mean · score on a scale
Change From Baseline in Clinicians Global Impression of Cough Severity Score (CGI-S) at Day 21
score on a scaleNAL ERPlacebo
Change From Baseline in Clinicians Global Impression of Cough Severity Score (CGI-S) at Day 21-1.02 ± 0.700-0.36 ± 0.672
Statistical analysis
  • NAL ER vs Placebo · Paired t-Test · p = <0.0001 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: -0.64 · 95% CI -0.9 to -0.4
SecondaryClinicians Global Impression of Change for Cough Score (CGI-C) at Day 21

The PGI-C Cough scale is an investigator-reported, single-item categorical scale that is increasingly used when assessing the investigator's belief of the participant's overall improvement pre-treatment baseline. Investigator rate the change in improvement in the last week with a 7-point Likert scale ranging from 1 to 7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6= Much worse, or 7= Very much worse). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.

Time frame:
Day 21
Reported as:
Mean · score on a scale
Clinicians Global Impression of Change for Cough Score (CGI-C) at Day 21
score on a scaleNAL ERPlacebo
Clinicians Global Impression of Change for Cough Score (CGI-C) at Day 212.23 ± 0.9343.50 ± 0.874
Statistical analysis
  • NAL ER vs Placebo · Paired t-Test · p = <0.0001 (Paired t-test was used to compare the mean change from baseline is different between planned treatments (NAL ER vs placebo).) · Mean difference: -1.23 · 95% CI -1.6 to -0.8

Adverse events

Collected over Up to Week 15. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NAL ER0/63 (0%)0/63 (0%)50/63 (79.4%)
Placebo0/59 (0%)0/59 (0%)32/59 (54.2%)
Most frequent other events
Showing 10 of 96
Most frequent other events
EventNAL ERPlacebo
ConstipationGastrointestinal disorders18/634/59
SomnolenceNervous system disorders16/630/59
NauseaGastrointestinal disorders14/632/59
DizzinessNervous system disorders12/632/59
HeadacheNervous system disorders10/637/59
FatigueGeneral disorders9/633/59
VomitingGastrointestinal disorders6/631/59
Dry mouthGastrointestinal disorders5/631/59
NasopharyngitisInfections and infestations4/632/59
DiarrhoeaGastrointestinal disorders3/633/59

Baseline characteristics

The Safety Population consisted of all participants who had received at least one dose of NAL ER or Placebo.

Age, Continuous
Age, Continuous(years)First NAL ER Then PlaceboFirst Placebo Then NAL ERTotal
Mean63.0 ± 9.1657.2 ± 11.0860.2 ± 10.47
Sex: Female, Male
Sex: Female, Male(Participants)First NAL ER Then PlaceboFirst Placebo Then NAL ERTotal
Female232144
Male111122
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)First NAL ER Then PlaceboFirst Placebo Then NAL ERTotal
Hispanic or Latino000
Not Hispanic or Latino343266
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)First NAL ER Then PlaceboFirst Placebo Then NAL ERTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American314
White313061
More than one race000
Unknown or Not Reported000
24-hour Cough Frequency
24-hour Cough Frequency(coughs per hour)First NAL ER Then PlaceboFirst Placebo Then NAL ERTotal
Mean45.869 ± 54.759326.374 ± 24.896836.287 ± 43.5333
08

Study locations

14 sites
  • McMaster University Medical Centre
    Hamilton, Ontario L8N 3Z5, Canada
  • Inspiration Research
    Toronto, Ontario M5T 3A9, Canada
  • CIC Mauricie Inc.
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital
    Cottingham, East Riding Of Yorkshire HU16 5JQ, United Kingdom
  • Kings College Hospital NHS Foundation Trust
    London, Greater London SE5 9RS, United Kingdom
  • University Hospital of South Manchester NHS Foundation Trust (UHSM) - Wythenshawe Hospital
    Manchester, Greater Manchester M23 9LT, United Kingdom
  • Accellacare South London
    Orpington, Kent BR5 3QG, United Kingdom
  • Accellacare North London
    Northwood, Middlesex HA6 2RN, United Kingdom
  • Belfast City Hospital
    Belfast, Northern Ireland BT9 7AB, United Kingdom
  • North Tyneside General Hospital - Northumbria Healthcare NHS Foundation Trust
    North Shields, Tynemouth NE29 8NH, United Kingdom
  • Accellacare Warwickshire
    Coventry, Warwickshire CV3 4FJ, United Kingdom
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, West Midlands B15 2GW, United Kingdom
  • Accellacare Yorkshire
    Shipley, Yorkshire BD18 3SA, United Kingdom
  • Egin Research Ltd
    High Wycombe, HP11 2QW, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jan 2025, 13 months.

Results were first posted in Mar 2026, 1 year 2 months after primary completion.

Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 13 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Jul 27, 2023
StartActual
Nov 30, 2023
Primary completionActual
Jan 6, 2025
CompletionActual
Jan 6, 2025
Results first posted
Mar 30, 2026
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05962151
Lead sponsor
Trevi Therapeutics
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Nov 30, 2023
Primary completion
Jan 6, 2025
Completion
Jan 6, 2025
Results posted
Mar 30, 2026
Last update
Mar 30, 2026

Study contacts

Chief Development Officer
study director · Trevi Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine

Start the discussion